Access the full text.
Sign up today, get DeepDyve free for 14 days.
P. Deedwania, M. Gupta, M. Stein, J. Yčas, A. Gold (2007)
Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial).The American journal of cardiology, 99 11
A. Middleton, A. Fuat (2006)
Achieving lipid goals in real life: the DISCOVERY-UK studyBr J Cardiol, 13
Paul Martin, J. Kemp, A. Dane, M. Warwick, D. Schneck (2002)
No Effect of Rosuvastatin on the Pharmacokinetics of Digoxin in Healthy VolunteersThe Journal of Clinical Pharmacology, 42
R. Kasliwal, L. Wilton, V. Cornelius, B. Aurich-Barrera, S. Shakir (2007)
Safety Profile of RosuvastatinDrug Safety, 30
Jiawei Chen, Dayuan Li, R. Schaefer, J. Mehta (2004)
Inhibitory Effect of Candesartan and Rosuvastatin on CD40 and MMPs Expression in Apo-E Knockout Mice: Novel Insights into the Role of RAS and Dyslipidemia in AtherogenesisJournal of Cardiovascular Pharmacology, 44
K. Cooper, Paul Martin, A. Dane, M. Warwick, A. Raza, D. Schneck (2003)
The effect of erythromycin on the pharmacokinetics of rosuvastatinEuropean Journal of Clinical Pharmacology, 59
B. Chu, T.S. Hatsukami, N.L. Polissar (2004)
Stroke
Paul Martin, A. Dane, D. Schneck, M. Warwick (2003)
An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers.Clinical therapeutics, 25 2
J. Chen, D. Li, R.F. Schaefer (2004)
J Cardiovasc Pharmacol
Geoffrey Holdgate, Walter Ward, F. McTaggart (2003)
Molecular mechanism for inhibition of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase by rosuvastatin.Biochemical Society transactions, 31 Pt 3
A. Link, Tarek Ayadhi, M. Böhm, G. Nickenig (2006)
Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome.European heart journal, 27 24
M. Cziraky, V. Willey, J. Mckenney, S. Kamat, M. Fisher, J. Guyton, T. Jacobson, M. Davidson (2006)
Statin safety: an assessment using an administrative claims database.The American journal of cardiology, 97 8A
Peter Jones, D. Hunninghake, K. Ferdinand, E. Stein, A. Gold, R. Caplan, J. Blasetto (2004)
Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial.Clinical therapeutics, 26 9
U. Resch, F. Tatzber, A. Budinsky, H. Sinzinger (2006)
Reduction of oxidative stress and modulation of autoantibodies against modified low-density lipoprotein after rosuvastatin therapy.British journal of clinical pharmacology, 61 3
P. Bonetti, L. Lerman, Claudio Napoli, Claudio Napoli, A. Lerman (2003)
Statin effects beyond lipid lowering--are they clinically relevant?European heart journal, 24 3
C. Furman, C. Copin, M. Kandoussi (2004)
Atherosclerosis
J. Mckenney, M. Davidson, T. Jacobson, J. Guyton (2006)
Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force.The American journal of cardiology, 97 8A
C. Furman, C. Copin, M. Kandoussi, R. Davidson, M. Moreau, Fergus McTaggiart, M. Chapman, J. Fruchart, M. Rouis (2004)
Rosuvastatin reduces MMP-7 secretion by human monocyte-derived macrophages: potential relevance to atherosclerotic plaque stability.Atherosclerosis, 174 1
M. Koren, D. Hunninghake (2004)
Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study.Journal of the American College of Cardiology, 44 9
W. Goettsch, E. Heintjes, J. Kastelein, T. Rabelink, S. Johansson, R. Herings (2006)
Results from a rosuvastatin historical cohort study in more than 45 000 Dutch statin users, a PHARMO studyPharmacoepidemiology and Drug Safety, 15
G. Smith, R. Davidson, S. Bloor (2000)
Pharmacological properties of ZD4522: a new HMG-CoA reductase inhibitor [abstract no. MoP20:W6]Atherosclerosis, 151
S.M. Grundy, J.I. Cleeman, C.N.B. Merz (2004)
J Am Coll Cardiol
N. Werner, J. Priller, U. Laufs, M. Endres, M. Böhm, U. Dirnagl, G. Nickenig (2002)
Bone Marrow–Derived Progenitor Cells Modulate Vascular Reendothelialization and Neointimal Formation: Effect of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase InhibitionArteriosclerosis, Thrombosis, and Vascular Biology: Journal of the American Heart Association, 22
B. Fellström, F. Zannad, R. Schmeider (2005)
Curr Control Trials Cardiovasc Med
M. Bots, J. Raichlen, G. Evans, M. Palmer, D. O'leary, D. Grobbee, J. Crouse (2007)
Abstract 194: Rosuvastatin Reduces Progression of Carotid Atherosclerosis within 12 Months of Treatment: The METEOR TrialCirculation, 116
R. Blumenthal, N. Kapur (2006)
Can a potent statin actually regress coronary atherosclerosis?JAMA, 295 13
J. Shepherd, D. Vidt, Elinor Miller, S. Harris, J. Blasetto (2007)
Safety of Rosuvastatin: Update on 16,876 Rosuvastatin-Treated Patients in a Multinational Clinical Trial ProgramCardiology, 107
A. McAfee, E. Ming, J. Seeger, Sherry Quinn, E. Ng, Jared Danielson, Jennifer Cutone, J. Fox, A. Walker (2006)
The comparative safety of rosuvastatin: a retrospective matched cohort study in over 48 000 initiators of statin therapyPharmacoepidemiology and Drug Safety, 15
J. Crouse, J. Raichlen, W. Riley, G. Evans, M. Palmer, D. O'leary, D. Grobbee, M. Bots (2007)
Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial.JAMA, 297 12
D. Wood, G. Backer, O. Faergeman, I. Graham, G. Mancia, K. Pyörälä (1998)
Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention.Atherosclerosis, 140 2
H. Schuster, P. Barter, S. Stender, R. Cheung, J. Bonnet, J. Morrell, C. Watkins, D. Kallend, A. Raza (2004)
Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy (MERCURY I) study.American heart journal, 147 4
H. Underhill, C. Yuan, Xue-Qiao Zhao, L. Kraiss, D. Parker, T. Saam, B. Chu, N. Takaya, Fei Liu, N. Polissar, B. Neradilek, J. Raichlen, V. Cain, J. Waterton, W. Hamar, T. Hatsukami (2008)
Effect of rosuvastatin therapy on carotid plaque morphology and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial.American heart journal, 155 3
L. Buckett, P. Ballard, R. Davidson, C. Dunkley, L. Martin, J. Stafford, F. McTaggart (2000)
Selectivity of ZD4522 for inhibition of cholesterol synthesis in hepatic versus non-hepatic cellsAtherosclerosis, 151
Bengt Fellström, Faiez Zannad, Roland Schmieder, H. Holdaas, Alan Jardine, H. Rose, W. Wilpshaar (2005)
Effect of rosuvastatin on outcomes in chronic haemodialysis patients – design and rationale of the AURORA studyCurrent Controlled Trials in Cardiovascular Medicine, 6
T. Takayama, T. Hiro, M. Yamagishi, H. Daida, S. Saito, T. Yamaguchi, M. Matsuzaki (2007)
Rationale and design for a study using intravascular ultrasound to evaluate effects of rosuvastatin on coronary artery atheroma in Japanese subjects: COSMOS study (Coronary Atherosclerosis Study Measuring Effects of Rosuvastatin Using Intravascular Ultrasound in Japanese Subjects).Circulation journal : official journal of the Japanese Circulation Society, 71 2
K. Nezasa, K. Higaki, Tadahiko Matsumura, K. Inazawa, H. Hasegawa, M. Nakano, M. Koike (2002)
Liver-specific distribution of rosuvastatin in rats: comparison with pravastatin and simvastatin.Drug metabolism and disposition: the biological fate of chemicals, 30 11
K.J. Cooper, P.D. Martin, A.L. Dane (2003)
Clin Pharmacol Ther
T. Pedersen, O. Faergeman, J. Kastelein, A. Olsson, M. Tikkanen, I. Holme, M. Larsen, F. Bendiksen, Christina Lindahl, M. Szarek, J. Tsai (2005)
High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.JAMA, 294 19
K.J. Cooper, P.D. Martin, A.L. Dane (2002)
Eur J Clin Pharmacol
B. Chu, T. Hatsukami, N. Polissar, Xue-Qiao Zhao, L. Kraiss, D. Parker, J. Waterton, J. Raichlen, W. Hamar, C. Yuan (2004)
Determination of Carotid Artery Atherosclerotic Lesion Type and Distribution in Hypercholesterolemic Patients With Moderate Carotid Stenosis Using Noninvasive Magnetic Resonance ImagingStroke, 35
S. Simonson, Paul Martin, P. Mitchell, K. Lasseter, G. Gibson, D. Schneck (2005)
Effect of Rosuvastatin on Warfarin Pharmacodynamics and PharmacokineticsThe Journal of Clinical Pharmacology, 45
A. Oren, L. Vos, C. Uiterwaal, D. Grobbee, M. Bots (2003)
Cardiovascular risk factors and increased carotid intima-media thickness in healthy young adults: the Atherosclerosis Risk in Young Adults (ARYA) Study.Archives of internal medicine, 163 15
W. Brown, H. Bays, D. Hassman, J. Mckenney, R. Chitra, H. Hutchinson, Elinor Miller (2002)
Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial.American heart journal, 144 6
Paul Martin, P. Mitchell, D. Schneck (2002)
Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers.British journal of clinical pharmacology, 54 5
Paul Martin, M. Warwick, A. Dane, C. Brindley, Tracy Short (2003)
Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers.Clinical therapeutics, 25 10
J. Kjekshus, E. Apetrei, V. Barrios, M. Böhm, J. Cleland, J. Cornel, P. Dunselman, C. Fonseca, A. Goudev, P. Grande, L. Gullestad, Å. Hjalmarson, J. Hradec, A. Jánosi, G. Kamenský, M. Komajda, J. Korewicki, T. Kuusi, F. Mach, V. Mareev, J. McMurray, N. Ranjith, M. Schaufelberger, J. Vanhaecke, D. Veldhuisen, F. Waagstein, H. Wedel, J. Wikstrand (2007)
Rosuvastatin in older patients with systolic heart failure.The New England journal of medicine, 357 22
P.D. Martin, A.L. Dane, D.W. Schneck (2003)
Clin Ther
A. Link, T. Ayadhi, M. Böhm (2006)
Eur Heart J
M.L. Bots, J.S. Raichlen, G.W. Evans (2007)
Rosuvastatin reduces progression of carotid atherosclerosis within 12 months of treatment: the METEOR trial [abstract no. 194]Circulation, 116
Graham Smith, R. Davidson, S. Bloor, K. Burns, C. Calnan, P. McAulay, N. Torr, W. Ward, F. McTaggart (2000)
Pharmacological properties of ZD4522 — A new HMG-CoA reductase inhibitorAtherosclerosis, 151
J. Schaefer, H. Schweer, K. Ikewaki, H. Stracke, H. Seyberth, H. Kaffarnik, B. Maisch, A. Steinmetz (1999)
Metabolic basis of high density lipoproteins and apolipoprotein A-I increase by HMG-CoA reductase inhibition in healthy subjects and a patient with coronary artery disease.Atherosclerosis, 144 1
M.B. Clearfield, J. Amerena, J.-P. Bassand (2006)
Trials
S.E. Nissen, E.M. Tuzcu, P. Schoenhagen (2004)
JAMA
C.M. Ballantyne, R. Weiss, T. Moccetti (2007)
Am J Cardiol
M. Lauer (2007)
Primary prevention of atherosclerotic cardiovascular disease: the high public burden of low individual risk.JAMA, 297 12
N. Kapur (2007)
Rosuvastatin: a highly potent statin for the prevention and management of coronary artery diseaseExpert Review of Cardiovascular Therapy, 5
K. Cooper, Paul Martin, A. Dane, M. Warwick, A. Raza, D. Schneck (2003)
Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjects.British journal of clinical pharmacology, 55 1
W.G. Goettsch, E.M. Heintjes, J.J.P. Kastelein (2006)
Pharmacoepidemiol Drug Saf
W. Insull, J. Ghali, D. Hassman, Joseph As, S. Gandhi, Elinor Miller (2007)
Achieving low-density lipoprotein cholesterol goals in high-risk patients in managed care: comparison of rosuvastatin, atorvastatin, and simvastatin in the SOLAR trial.Mayo Clinic proceedings, 82 5
P.D. Martin, J. Kemp, A.L. Dane (2002)
J Clin Pharmacol
C.D.A. Brown, A. Windass, K. Bleasby (2001)
Rosuvastatin is a high affinity substrate of hepatic organic anion transporter OATP-C [abstract no. 166]Atheroscler, 2
M. Clearfield, J. Amerena, J. Bassand, Hugo García, Sam Miller, F. Sosef, M. Palmer, B. Bryzinski (2006)
Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia – Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR)Trials, 7
Paul Martin, A. Dane, O. Nwose, D. Schneck, M. Warwick (2002)
No Effect of Age or Gender on the Pharmacokinetics of Rosuvastatin: A New HMG‐CoA Reductase InhibitorThe Journal of Clinical Pharmacology, 42
Peter Jones, M. Davidson, E. Stein, H. Bays, J. Mckenney, Elinor Miller, V. Cain, J. Blasetto (2003)
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).The American journal of cardiology, 92 2
G.W. Evans, J.S. Raichlen, M.L. Bots (2007)
Rosuvastatin treatment in carotid atherosclerosis: effect of Framingham risk factors and baseline intima-media thickness in the METEOR trial [abstract no. 3730]Circulation, 116
A. Middleton, A. Binbrek, F. Fonseca, W. Wilpshaar, C. Watkins, T. Strandberg (2006)
Achieving 2003 European lipid goals with rosuvastatin and comparator statins in 6743 patients in real-life clinical practice: DISCOVERY meta-analysisCurrent Medical Research and Opinion, 22
Q. Gong, Li Zhang, G. Vincent, B. Horne, Zhengfeng Zhou (2007)
Nonsense Mutations in hERG Cause a Decrease in Mutant mRNA Transcripts by Nonsense-Mediated mRNA Decay in Human Long-QT SyndromeCirculation, 116
K.-I. Nezasa, K. Higaki, T. Matsumura (2002)
Drug Metab Dispos
Guy Backer(Chairperson), E. Ambrosioni, K. Borch-Johnsen, C. Brotons, R. Cífková, J. Dallongeville, S. Ebrahim, O. Faergeman, I. Graham, G. Mancia, V. Cats, K. Orth-Gomér, J. Perk, K. Pyörälä, J. Rodicio, S. Sans, V. Sansoy, U. Sechtem, S. Silber, T. Thomsen, D. Wood (2003)
European guidelines on cardiovascular disease prevention in clinical practice; Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts)European Journal of Preventive Cardiology, 10
W. Insull, J.K. Ghali, D.R. Hassman (2007)
Mayo Clin Proc
T. Lu, Y. Ding, H. Leu, W. Yin, W. Sheu, K. Chu (2004)
Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia.The American journal of cardiology, 94 2
E. Lee, Stephen Ryan, B. Birmingham, Julie Zalikowski, R. March, H. Ambrose, Rachael Moore, Caroline Lee, Yusong Chen, D. Schneck (2005)
Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environmentClinical Pharmacology & Therapeutics, 78
L. Jensen, P. Thayssen, K. Pedersen, S. Stender, T. Haghfelt (2004)
Regression of Coronary Atherosclerosis by Simvastatin: A Serial Intravascular Ultrasound StudyCirculation: Journal of the American Heart Association, 110
L. Scott, M. Curran, D. Figgitt (2004)
Rosuvastatin: a review of its use in the management of dyslipidemia.American journal of cardiovascular drugs : drugs, devices, and other interventions, 4 2
A. Olsson, H. Istad, O. Luurila, L. Ose, S. Stender, J. Tuomilehto, O. Wiklund, H. Southworth, J. Pears, J. Wilpshaar (2002)
Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia.American heart journal, 144 6
S. Nissen, S. Nicholls, I. Sipahi, P. Libby, J. Raichlen, C. Ballantyne, J. Davignon, R. Erbel, J. Tardif, P. Schoenhagen, T. Crowe (2006)
Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.JAMA, 295 13
A. Oren, L.E. Vos, C.S.P.M. Uiterwaal (2003)
Arch Intern Med
C. Ballantyne, R. Weiss, T. Moccetti, A. Vogt, B. Eber, F. Sosef, E. Duffield (2007)
Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study).The American journal of cardiology, 99 5
R. Lloret, J. Yčas, M. Stein, S. Haffner (2006)
Comparison of rosuvastatin versus atorvastatin in Hispanic-Americans with hypercholesterolemia (from the STARSHIP trial).The American journal of cardiology, 98 6
K. Ferdinand, L. Clark, K. Watson, R. Neal, C. Brown, B. Kong, B. Barnes, W. Cox, F. Zieve, J. Isaacsohn, J. Yčas, P. Sager, A. Gold (2006)
Comparison of efficacy and safety of rosuvastatin versus atorvastatin in African-American patients in a six-week trial.The American journal of cardiology, 97 2
S. Okazaki, T. Yokoyama, K. Miyauchi, K. Shimada, T. Kurata, Hitoshi Sato, H. Daida (2004)
Early Statin Treatment in Patients With Acute Coronary Syndrome: Demonstration of the Beneficial Effect on Atherosclerotic Lesions by Serial Volumetric Intravascular Ultrasound Analysis During Half a Year After Coronary Event: The ESTABLISH StudyCirculation, 110
H. Schuster (2007)
Expert Rev Cardiovasc Ther
P. Davis, J. Dawson, W. Riley, R. Lauer (2001)
Carotid Intimal-Medial Thickness Is Related to Cardiovascular Risk Factors Measured From Childhood Through Middle Age: The Muscatine StudyCirculation: Journal of the American Heart Association, 104
O. Faergeman, F. Sosef, E. Duffield (2006)
Th-P16:394 Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in high-risk patients: Results from the eclipse studyAtherosclerosis Supplements, 7
N. Werner, J. Priller, U. Laufs (2002)
Arterioscler Thromb Vasc Biol
E. Ooi, G. Watts, P. Nestel, D. Sviridov, A. Hoang, P. Barrett (2008)
Dose-dependent regulation of high-density lipoprotein metabolism with rosuvastatin in the metabolic syndrome.The Journal of clinical endocrinology and metabolism, 93 2
Jane Thomas, S. Paranjothy, D. James (2004)
National cross sectional survey to determine whether the decision to delivery interval is critical in emergency caesarean sectionBMJ : British Medical Journal, 328
S.G. Simonson, P.D. Martin, M.J. Warwick (2004)
Br J Clin Pharmacol
G. Evans, J. Raichlen, M. Bots, M. Palmer, D. O'leary, D. Grobbee, J. Crouse (2007)
Abstract 3730: Rosuvastatin Treatment in Carotid Atherosclerosis: Effect of Framingham Risk Factors and Baseline Intima-Media Thickness in the METEOR TrialCirculation, 116
A. Oostrom, H. Plokker, B. Asbeck, T. Rabelink, K. Kessel, E. Jansen, C. Stehouwer, M. Cabezas (2006)
Effects of rosuvastatin on postprandial leukocytes in mildly hyperlipidemic patients with premature coronary sclerosis.Atherosclerosis, 185 2
T. Strandberg, J. Feely, E. Sigurdsson (2004)
Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.Clinical therapeutics, 26 11
J. Kjekshus, E. Apetrei, V. Barrios (2007)
N Engl J Med
D. Schneck, R. Knopp, C. Ballantyne, R. McPherson, R. Chitra, S. Simonson (2003)
Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease.The American journal of cardiology, 91 1
A.F.E. Bots, J. Kastelein (2005)
Int J Clin Pract
C. Ballantyne, M. Bertolami, Hugo Garcia, D. Nul, E. Stein, P. Théroux, R. Weiss, V. Cain, J. Raichlen (2006)
Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II.American heart journal, 151 5
P. Ridker (2003)
Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial.Circulation, 108 19
H. Schuster (2003)
Rosuvastatin – A Highly Effective New 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor: Review of Clinical Trial Data at 10–40 mg Doses in Dyslipidemic PatientsCardiology, 99
J. Larosa, S. Grundy, D. Waters, C. Shear, P. Barter, J. Fruchart, A. Gotto, H. Greten, J. Kastelein, J. Shepherd, N. Wenger (2005)
Intensive lipid lowering with atorvastatin in patients with stable coronary disease.The New England journal of medicine, 352 14
S. Bergheanu, A. Tol, G. Dallinga-Thie, Anho Liem, P. Dunselman, J. Bom, J. Jukema (2007)
Effect of rosuvastatin versus atorvastatin treatment on paraoxonase-1 activity in men with established cardiovascular disease and a low HDL-cholesterolCurrent Medical Research and Opinion, 23
L Buckett, P Ballard, R Davidson (2000)
Selectivity of ZD4522 for inhibition of cholesterol synthesis in hepatic versus non-hepatic cells [abstract no. MoP29:W6]Atherosclerosis, 157
Lawrence Leiter, R. Rosenson, E. Stein, J. Reckless, K. Schulte, M. Schleman, P. Miller, M. Palmer, F. Sosef (2007)
Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study.Atherosclerosis, 194 2
E. Avest, E. Abbink, S. Holewijn, J. Graaf, C. Tack, A. Stalenhoef (2005)
Effects of rosuvastatin on endothelial function in patients with familial combined hyperlipidaemia (FCH)Current Medical Research and Opinion, 21
R. Kasliwal, L.V. Wilton, V. Cornelius (2007)
Safety profile of rosuvastatin: results of a prescription-event monitoring study of 11 680 patientsDrug Saf, 30
V. Serebruany, Michael Miller, A. Pokov, A. Malinin, D. Lowry, J. Tanguay, C. Hennekens (2006)
Effect of statins on platelet PAR-1 thrombin receptor in patients with the metabolic syndrome (from the PAR-1 inhibition by statins [PARIS] study).The American journal of cardiology, 97 9
S. Nissen, E. Tuzcu, P. Schoenhagen, B. Brown, Peter Ganz, Robert Vogel, T. Crowe, Gail Howard, Christopher Cooper, Bruce Brodie, C. Grines, Anthony DeMaria (2004)
Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial.JAMA, 291 9
H.R. Underhill, C. Yuan, X.-Q. Zhao (2008)
Am Heart J
John LaRosa (2001)
Pleiotropic effects of statins and their clinical significance.The American journal of cardiology, 88 3
E.M.M. Ooi, G.F. Watts, P.J. Nestel (2008)
J Clin Endocrinol Metab
Cooper K., Martin P., Dane A., Warwick M., Schneck D., Cantarini M. (2002)
The effect of fluconazole on the pharmacokinetics of rosuvastatinEuropean Journal of Clinical Pharmacology, 58
T. Kosoglou, P. Statkevich, Bo Yang, R. Suresh, Yali Zhu, T. Boutros, S. Maxwell, R. Tiessen, D. Cutler (2004)
Pharmacodynamic interaction between ezetimibe and rosuvastatinCurrent Medical Research and Opinion, 20
H. Schuster (2007)
The GALAXY Program: an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular riskExpert Review of Cardiovascular Therapy, 5
Colin Brown, A. Windass, K. Bleasby, B. Lauffart (2001)
Rosuvastatin is a high affinity substrate of hepatic organic anion transporter OATP-CAtherosclerosis Supplements, 2
W. Taylor, N. Unwin (2009)
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Detection, Evaluation, and Treatment of High Blood Cholesterol Education Program (NCEP) Expert Panel on Executive Summary of the Third Report of the National
E. Avest, E.J. Abbink, S. Holewijn (2005)
Curr Med Res Opin
A. Stalenhoef, C. Ballantyne, C. Sarti, J. Murín, S. Tonstad, H. Rose, W. Wilpshaar (2005)
A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study.European heart journal, 26 24
T. Takayama, T. Hiro, M. Yamagishi (2007)
Circ J
R. Paoletti, M. Fahmy, G. Mahla (2001)
Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: a randomized, double-blind studyJ Cardiovasc Risk, 8
G. Backer, E. Ambrosioni, K. Borch-Johnsen (2003)
European guidelines on cardiovascular disease prevention in clinical practiceEur J Cardiovasc Prev Rehabil, 10
Paul Martin, M. Warwick, A. Dane, M. Cantarini (2003)
A double-blind, randomized, incomplete crossover trial to assess the dose proportionality of rosuvastatin in healthy volunteers.Clinical therapeutics, 25 8
K. Schäfer, K. Kaiser, S. Konstantinides (2004)
Rosuvastatin exerts favourable effects on thrombosis and neointimal growth in a mouse model of endothelial injuryThrombosis and Haemostasis, 93
A. Binbrek, A. Elis, M. Al-Zaibag, J. Eha, I. Keber, A. Cuevas, Swati Mukherjee, Thomas Miller (2006)
Rosuvastatin versus atorvastatin in achieving lipid goals in patients at high risk for cardiovascular disease in clinical practice: A randomized, open-label, parallel-group, multicenter study (DISCOVERY Alpha study).Current therapeutic research, clinical and experimental, 67 1
Paul Martin, M. Warwick, A. Dane, S. Hill, P. Giles, P. Phillips, E. Lenz (2003)
Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers.Clinical therapeutics, 25 11
S. Grundy, J. Cleeman, C Noel, B. Merz, H Brewer, L. Clark, D. Hunninghake, R. Pasternak, Sidney Smith, N. Stone (2004)
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.Journal of the American College of Cardiology, 44 3
P. Ridker (2003)
Circulation
D.J. Betteridge, J. Gibson (2007)
Diabet Med
M. Davidson, P. Ma, E. Stein, A. Gotto, A. Raza, R. Chitra, H. Hutchinson (2002)
Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia.The American journal of cardiology, 89 3
R. Paoletti, Maurice Fahmy, G. Mahla, Jacques Mizan, H. Southworth (2001)
Rosuvastatin Demonstrates Greater Reduction of Low-Density Lipoprotein Cholesterol Compared with Pravastatin and Simvastatin in Hypercholesterolaemic Patients: A Randomized, Double-Blind StudyEuropean Journal of Cardiovascular Prevention & Rehabilitation, 8
Jun-ren Zhu, B. Tomlinson, Y. Ro, K. Sim, Yuan-Teh Lee, C. Sriratanasathavorn (2007)
A randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY-Asia study)Current Medical Research and Opinion, 23
ment of dyslipidemia, and was recently approved in the US to slow the progression of atherosclerosis as part of a strategy to lower low-density lipoprotein-cholesterol (LDL-C) and total cholesterol (TC) to target levels. Rosuvastatin has greater lipid-lowering efficacy than any of the other currently available statins, and significant- ly more patients receiving rosuvastatin than other statins achieve LDL-C goals. Rosuvastatin delayed the progression of carotid atherosclerosis in patients with subclinical carotid atherosclerosis, moderately elevated cholesterol levels, and a low risk of cardiovascular disease in a primary prevention trial (METEOR). The results of METEOR suggest a possible role for the earlier use of rosuvastatin in primary prevention, although more data are needed from trials examining the effects of the drug on cardiovascular endpoints. Significant regression of atherosclerosis was seen with rosuvastatin 40 mg/day in patients with established coronary heart disease (CHD) in the ASTEROID trial, supporting the use of intensive lipid lowering in secondary prevention patients (although it should be noted that it has not yet been established that atherosclerotic regression translates into improved cardiovascular outcomes). Rosuvastatin is generally well tolerated, with a similar tolerability profile to that of other currently available statins. Thus, rosuvastatin is an important lipid-lowering treatment
American Journal of Cardiovascular Drugs – Springer Journals
Published: Aug 20, 2012
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.